Artiva Biotherapeutics, Inc. Capital Expenditures
Artiva Biotherapeutics, Inc. (ARTV) reported Capital Expenditures of $657.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $415.00K, a 60.66% decline year-over-year.
- Artiva Biotherapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $242.00K, a 52.64% decline year-over-year.
- Artiva Biotherapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $421.00K, a 557.81% increase year-over-year.
- Artiva Biotherapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $600.00K, a 525.00% increase year-over-year.
- Artiva Biotherapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $2.59M, a 302.96% increase from fiscal 2024.
- Artiva Biotherapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $642.00K, a 80.29% decline from fiscal 2023.
- Artiva Biotherapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $3.26M.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $415.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $657.00K 10-Q · filed 2026-08-06 | $1.08M derived: sum of 3 quarters · filed 2026-08-06 | $1.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $242.00K 10-Q · filed 2026-05-08 | $663.00K derived: sum of 2 quarters · filed 2026-05-08 | $1.26M derived: sum of 3 quarters · filed 2026-05-08 | $2.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $421.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $1.02M derived: sum of 2 quarters · filed 2026-03-10 | $2.08M derived: sum of 3 quarters · filed 2026-08-06 | $2.59M 10-K · filed 2026-03-10 |
| 2025-09-30 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.66M derived: sum of 2 quarters · filed 2026-08-06 | $2.17M 10-Q · filed 2025-11-12 | $2.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.57M 10-Q · filed 2026-08-06 | $1.63M derived: sum of 3 quarters · filed 2026-08-06 | $1.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $511.00K 10-Q · filed 2026-05-08 | $575.00K derived: sum of 2 quarters · filed 2026-05-08 | $671.00K derived: sum of 3 quarters · filed 2026-05-08 | $1.14M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $160.00K derived: sum of 2 quarters · filed 2026-03-10 | $624.00K derived: sum of 3 quarters · filed 2026-03-10 | $642.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $560.00K derived: sum of 2 quarters · filed 2025-11-12 | $578.00K 10-Q · filed 2025-11-12 | $1.21M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $464.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $482.00K 10-Q · filed 2025-08-06 | $1.12M derived: sum of 3 quarters · filed 2025-08-06 | $1.30M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $18.00K 10-Q · filed 2025-05-08 | $654.00K derived: sum of 2 quarters · filed 2025-05-08 | $833.00K derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $636.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $815.00K derived: sum of 2 quarters · filed 2025-03-24 | $3.26M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $179.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.62M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $2.44M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |